Board Member
Lifecore Biomedical, Inc. De (LFCR)Equibles does not estimate personal net worth.
Get an email with a short summary when Lifecore Biomedical, Inc. De publishes a filing, an earnings call transcript or a press release.
Get LFCR alertsPaul Josephs is recorded as Board Member at Lifecore Biomedical, Inc. De (LFCR) since January 1, 2024 and CEO at Lifecore Biomedical, Inc. De (LFCR). The newest filing on record that lists Paul Josephs as CEO and Board Member at Lifecore Biomedical, Inc. De (LFCR) is dated April 24, 2026. Lifecore Biomedical, Inc. De reported in an 8-K filed June 5, 2026 that Paul Josephs was appointed Director, effective June 4, 2026. Lifecore Biomedical, Inc. De reported in an 8-K filed May 22, 2024 that Paul Josephs was appointed director, effective May 20, 2024. Lifecore Biomedical, Inc. De reported in an 8-K filed May 22, 2024 that Paul Josephs was appointed President and Chief Executive Officer, effective May 20, 2024. Equibles holds 5 filed executive changes naming Paul Josephs; each is listed under recent activity with its source filing. The proxy statement of Lifecore Biomedical, Inc. De reports total compensation of $1,115,305 for Paul Josephs in fiscal 2025, including a base salary of $550,000. Disclosed compensation is on record for 2 fiscal years. Paul Josephs has spoken on 8 earnings calls across 1 company, most recently for Lifecore Biomedical, Inc. De on August 5, 2026. Lifecore Biomedical, Inc. De is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Lifecore Biomedical, Inc. De includes Craig A. Barbarosh (Chairman), Katrina L. Houde (Chairman and Board Member), Brian McLaughlin (CFO) and 7 others.
“As a result of the foregoing voting results, each of the foregoing directors was elected to the Board of Directors of the Company to serve for a term expiring at the 2027 Annual Meeting and until their successors are duly elected and qualified, with seven such nominees elected by holders of Common Stock and holders of the Series A Preferred Stock, voting together as a single class, and the Series A Preferred Directors elected solely by holders of the Series A Preferred Stock.”
“On May 20, 2024, Paul Josephs began serving as the Company’s President and Chief Executive Officer and was elected as a director of the Company.”
“During the second quarter, Life Corps continued to execute with focus and discipline against the strategic objectives we implemented over the last 24 months. We are energized by the success and progress we are making in achieving the three pillars of our growth strategy.”
“During the first quarter of 2026, we continue to execute on each of the three pillars of our growth strategy. Maximizing our existing commercial business, advancing our development pipeline towards commercialization, and adding high-quality new programs to our pipeline through business development.”
“2025 was a highly productive year for Life Corps Biomedical. during which we strengthened our pipeline capabilities leadership and our standing as a differentiated CDMO during the year we continued to successfully execute against our strategy to position life core for sustained growth through which we aim to achieve a…”
“Good afternoon, everyone, and thank you for joining our Fiscal 2025 fourth quarter and full year update. Fiscal 2025 was a strong year for LifeCorp Biomedical. As you may recall, I joined the company in May 2024 and immediately began to tackle a number of challenges.”
“Good afternoon, everyone, and thank you for joining us for our fiscal 2025 third quarter update. During the third quarter, Lifecore continued to aggressively and successfully execute against our stated plan for the year, with noteworthy accomplishments across multiple areas of our business.”
2024-01-01–present
Last confirmed April 24, 2026
Start not stated–present
Last confirmed April 24, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Lifecore Biomedical, Inc. De (LFCR) | President and Chief Executive Officer | $550,000 | $1,115,305 |
| 2024 | Lifecore Biomedical, Inc. De (LFCR) | President and Chief Executive Officer | $10,557 | $10,247,057 |
